Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: an individual participant data meta-analysis.


Journal

Sleep medicine
ISSN: 1878-5506
Titre abrégé: Sleep Med
Pays: Netherlands
ID NLM: 100898759

Informations de publication

Date de publication:
01 2021
Historique:
received: 22 02 2020
revised: 02 04 2020
accepted: 07 04 2020
pubmed: 28 8 2020
medline: 22 6 2021
entrez: 27 8 2020
Statut: ppublish

Résumé

Chronic intermittent hypoxia occurring in obstructive sleep apnea (OSA) is independently associated with nonalcoholic fatty liver disease (NAFLD). Chronic obstructive pulmonary disease (COPD) has also been suggested to be linked with liver disease. In this individual participant data meta-analysis, we investigated the association between liver damage and OSA and COPD severity. Patients suspected of OSA underwent polysomnography (PSG) or home sleep apnea testing (HSAT). Non-invasive tests were used to evaluate liver steatosis (Hepatic Steatosis Index) and fibrosis (Fibrotest or FibroMeter). An individual participant data meta-analysis approach was used to determine if the severity of OSA/COPD affects the type and severity of liver disease. Results were confirmed by multivariate and causal mediation analysis. Sub-group analyses were performed to investigate specific populations. Among 2120 patients, 1584 had steatosis (75%). In multivariable analysis, risk factors for steatosis were an apnea-hypopnea index (AHI) > 5/h, body mass index (BMI) > 26 kg/m This meta-analysis confirms the strong association between steatosis and the severity of OSA. The relation between OSA and fibrosis is mainly due to BMI as shown by causal mediation analysis.

Identifiants

pubmed: 32843301
pii: S1389-9457(20)30165-9
doi: 10.1016/j.sleep.2020.04.004
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

357-364

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Ingrid Jullian-Desayes (I)

HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France; EFCR Laboratory, Pole Thorax et Vaisseaux, Grenoble Alps University Hospital, Grenoble, France.

Wojciech Trzepizur (W)

Department of Respiratory Diseases, Angers University Hospital, Angers, France; INSERM U1063, SOPAM, Angers University, F-49045, Angers, France.

Jérôme Boursier (J)

Hepato-Gastroenterology Department, Angers University Hospital, Angers, France; HIFIH Laboratory, UPRES 3859, SFR 4208, Angers University, Angers, France.

Marie Joyeux-Faure (M)

HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France; EFCR Laboratory, Pole Thorax et Vaisseaux, Grenoble Alps University Hospital, Grenoble, France.

Sébastien Bailly (S)

HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France; EFCR Laboratory, Pole Thorax et Vaisseaux, Grenoble Alps University Hospital, Grenoble, France.

Meriem Benmerad (M)

HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France; EFCR Laboratory, Pole Thorax et Vaisseaux, Grenoble Alps University Hospital, Grenoble, France.

Marc Le Vaillant (M)

Institut Recherche en Santé Respiratoire des Pays de la Loire, Beaucouzé, France.

Sandrine Jaffre (S)

Institut du Thorax, Department of Respiratory Diseases, Nantes University Hospital, Nantes, France.

Thierry Pigeanne (T)

Respiratory Unit, Pôle Santé des Olonnes, Olonne sur Mer, France.

Acya Bizieux-Thaminy (A)

Department of Respiratory Diseases, General Hospital, La Roche sur Yon, France.

Marie-Pierre Humeau (MP)

Department of Respiratory Diseases, Nouvelles Cliniques Nantaises, Nantes, France.

Claire Alizon (C)

Department of Respiratory Diseases, General Hospital, Cholet, France.

François Goupil (F)

Department of Respiratory Diseases, General Hospital, Le Mans, France.

Charlotte Costentin (C)

Hepatogastroenterology Department, Grenoble Alpes University Hospital, Grenoble, France; INSERM U823, IAPC Institute for Advanced Biosciences, University Grenoble Alpes, Grenoble, France.

Jonathan Gaucher (J)

HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France.

Renaud Tamisier (R)

HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France; EFCR Laboratory, Pole Thorax et Vaisseaux, Grenoble Alps University Hospital, Grenoble, France.

Frédéric Gagnadoux (F)

Department of Respiratory Diseases, Angers University Hospital, Angers, France; INSERM U1063, SOPAM, Angers University, F-49045, Angers, France.

Jean-Louis Pépin (JL)

HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France; EFCR Laboratory, Pole Thorax et Vaisseaux, Grenoble Alps University Hospital, Grenoble, France. Electronic address: JPepin@chu-grenoble.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH